The mission of the Bioinformatics Shared Resource (BISR) is to provide bioinformatic and biostatistical collaboration, consultation, and quantitative research resources to clinical, laboratory, and prevention scientists engaged in the planning, conduct, analysis, and interpretation of research studies that use modern high-throughput technologies from molecular biology. Additionally, members of the BISR collaborate with oncology research scientists to develop bioinformatic and biostatistical methods to improve the efficiency of current and future basic science, therapeutic, diagnostic, prevention, and intervention studies. Members of the BISR have experience with mRNA expression microarrays from Affymetrix, Agilent, and Illumina, proteomics using mass spectrometry or two-dimensional polyacrylamide gel electrophoresis;serial analysis of gene expression;tissue microarrays;array comparative genomic hybridization;single nucleotide polymorphism chips;methylation arrays;microRNA arrays;exon tiling arrays;real-time polymerase chain reaction;and reverse-phase protein lysate arrays. The BISR provides advice on choosing technology platforms, experimental design, sample size and power computations, data preprocessing, statistical analysis, and bioinformatic interpretation. The services of the resource are directed toward three goals: (1) to ensure that all high-throughput experiments at M.D. Anderson are properly analyzed and interpreted, (2) to play a direct role in the planning and design of experiments that use these technologies, and (3) to provide educational programs in bioinformatics methods. During the previous funding period, the BISR assisted 244 investigators from 20 different programs. Use of the BISR doubled during the previous five years, and the number of publications by users of the BISR grew from 33 during the first year to 65 during the most recent year. In the future, we remain committed to providing support for the design and analysis of experiments using cutting-edge technologies and will work with M.D. Anderson researchers to understand the nature of the data generated from novel technologies. Where possible, we are standardizing our analyses and report generation by developing templates in Sweave, a tool that enhances the reproducibility of statistical analyses. We also plan to enhance our ability to offer sequence-based bioinformatics services such as ChlP-on-chip and motif finding. Finally, we are exploring innovative ways to integrate data, algorithms, and reports.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-36
Application #
8310862
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
36
Fiscal Year
2011
Total Cost
$166,099
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Murray, Thomas A; Yuan, Ying; Thall, Peter F et al. (2018) A utility-based design for randomized comparative trials with ordinal outcomes and prognostic subgroups. Biometrics 74:1095-1103
Sun, Lin-Lin; Yang, Ri-Yao; Li, Chia-Wei et al. (2018) Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing. Am J Cancer Res 8:1307-1316
Yam, Clinton; Xu, Xiaowei; Davies, Michael A et al. (2018) A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors. Clin Cancer Res 24:22-32
Veletic, Ivo; Manshouri, Taghi; Newberry, Kate J et al. (2018) Pentraxin-3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis. Br J Haematol :
El Fakih, Riad; Jabbour, Elias; Ravandi, Farhad et al. (2018) Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults. Am J Hematol 93:286-295
Sankhala, Kamalesh; Takimoto, Chris H; Mita, Alain C et al. (2018) Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules. Invest New Drugs :
Shen, Weining; Ning, Jing; Yuan, Ying et al. (2018) Model-free scoring system for risk prediction with application to hepatocellular carcinoma study. Biometrics 74:239-248
Wu, Shaofang; Wang, Shuzhen; Gao, Feng et al. (2018) Activation of WEE1 confers resistance to PI3K inhibition in glioblastoma. Neuro Oncol 20:78-91
Romano, Gabriele; Chen, Pei-Ling; Song, Ping et al. (2018) A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling. Cancer Discov 8:556-567
Dray, Beth K; Raveendran, Muthuswamy; Harris, R Alan et al. (2018) Mismatch repair gene mutations lead to lynch syndrome colorectal cancer in rhesus macaques. Genes Cancer 9:142-152

Showing the most recent 10 out of 12418 publications